PHLDA2 and hepatocellular carcinoma: As a downstream target of the DAGLA-activated YAP/TEAD2 axis, PHLDA2 could induce the EMT process and inhibit p57 activity in HCC cells (Fig. 6H, Supplementary Fig. S6C).